Selected research
Market Structure
Global Ophthalmic Steroids Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Ophthalmic Steroids Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Ophthalmic Steroids Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Ophthalmic Steroids Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Ophthalmic Steroids Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Ophthalmic Steroids Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Ophthalmic Steroids Drug include Alimera Sciences, Allergan, Bausch and Lomb, Genentech, Novartis AG, Regeneron Pharmaceuticals, Valeant Pharmaceuticals International, Bayer AG and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Ophthalmic Steroids Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Ophthalmic Steroids Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Ophthalmic Steroids Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ophthalmic Steroids Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Ophthalmic Steroids Drug Segment by Company
Alimera Sciences
Allergan
Bausch and Lomb
Genentech
Novartis AG
Regeneron Pharmaceuticals
Valeant Pharmaceuticals International
Bayer AG
GlaxoSmithKline
Pfizer
Ophthalmic Steroids Drug Segment by Type
Allergic Conjunctivitis
Keratitis
Uveitis
Diabetic Macular Edema
Others
Ophthalmic Steroids Drug Segment by Application
Retail Pharmacies
Online Pharmacies
Research Institute
Hospital Pharmacies
Others
Ophthalmic Steroids Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmic Steroids Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ophthalmic Steroids Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmic Steroids Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Ophthalmic Steroids Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ophthalmic Steroids Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ophthalmic Steroids Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Ophthalmic Steroids Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Allergic Conjunctivitis
- Keratitis
- Uveitis
- Diabetic Macular Edema
- Others
Applications
- Retail Pharmacies
- Online Pharmacies
- Research Institute
- Hospital Pharmacies
- Others
Companies covered
- Alimera Sciences
- Allergan
- Bausch and Lomb
- Genentech
- Novartis AG
- Regeneron Pharmaceuticals
- Valeant Pharmaceuticals International
- Bayer AG
- GlaxoSmithKline
- Pfizer
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Ophthalmic Steroids Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Ophthalmic Steroids Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Ophthalmic Steroids Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Ophthalmic Steroids Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Ophthalmic Steroids Drug Market Dynamics
- 2.1 Ophthalmic Steroids Drug Industry Trends
- 2.2 Ophthalmic Steroids Drug Industry Drivers
- 2.3 Ophthalmic Steroids Drug Industry Opportunities and Challenges
- 2.4 Ophthalmic Steroids Drug Industry Restraints
3 Ophthalmic Steroids Drug Market by Manufacturers
- 3.1 Global Ophthalmic Steroids Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Ophthalmic Steroids Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Ophthalmic Steroids Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Ophthalmic Steroids Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Ophthalmic Steroids Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Ophthalmic Steroids Drug Manufacturers, Product Type & Application
- 3.7 Global Ophthalmic Steroids Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Ophthalmic Steroids Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Ophthalmic Steroids Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Ophthalmic Steroids Drug Tier 1, Tier 2, and Tier 3
4 Ophthalmic Steroids Drug Market by Type
- 4.1 Ophthalmic Steroids Drug Type Introduction
- 4.1.1 Allergic Conjunctivitis
- 4.1.2 Keratitis
- 4.1.3 Uveitis
- 4.1.4 Diabetic Macular Edema
- 4.1.5 Others
- 4.2 Global Ophthalmic Steroids Drug Sales by Type
- 4.2.1 Global Ophthalmic Steroids Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Ophthalmic Steroids Drug Sales by Type (2021-2032)
- 4.2.3 Global Ophthalmic Steroids Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Ophthalmic Steroids Drug Revenue by Type
- 4.3.1 Global Ophthalmic Steroids Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Ophthalmic Steroids Drug Revenue by Type (2021-2032)
- 4.3.3 Global Ophthalmic Steroids Drug Revenue Market Share by Type (2021-2032)
5 Ophthalmic Steroids Drug Market by Application
- 5.1 Ophthalmic Steroids Drug Application Introduction
- 5.1.1 Retail Pharmacies
- 5.1.2 Online Pharmacies
- 5.1.3 Research Institute
- 5.1.4 Hospital Pharmacies
- 5.1.5 Others
- 5.2 Global Ophthalmic Steroids Drug Sales by Application
- 5.2.1 Global Ophthalmic Steroids Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Ophthalmic Steroids Drug Sales by Application (2021-2032)
- 5.2.3 Global Ophthalmic Steroids Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Ophthalmic Steroids Drug Revenue by Application
- 5.3.1 Global Ophthalmic Steroids Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Ophthalmic Steroids Drug Revenue by Application (2021-2032)
- 5.3.3 Global Ophthalmic Steroids Drug Revenue Market Share by Application (2021-2032)
6 Global Ophthalmic Steroids Drug Sales by Region
- 6.1 Global Ophthalmic Steroids Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Ophthalmic Steroids Drug Sales by Region (2021-2032)
- 6.2.1 Global Ophthalmic Steroids Drug Sales by Region (2021-2026)
- 6.2.2 Global Ophthalmic Steroids Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Ophthalmic Steroids Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Ophthalmic Steroids Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Ophthalmic Steroids Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Ophthalmic Steroids Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Ophthalmic Steroids Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Ophthalmic Steroids Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Ophthalmic Steroids Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Ophthalmic Steroids Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Ophthalmic Steroids Drug Revenue by Region
- 7.1 Global Ophthalmic Steroids Drug Revenue by Region
- 7.1.1 Global Ophthalmic Steroids Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Ophthalmic Steroids Drug Revenue by Region (2021-2026)
- 7.1.3 Global Ophthalmic Steroids Drug Revenue by Region (2027-2032)
- 7.1.4 Global Ophthalmic Steroids Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Ophthalmic Steroids Drug Revenue (2021-2032)
- 7.2.2 North America Ophthalmic Steroids Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Ophthalmic Steroids Drug Revenue (2021-2032)
- 7.3.2 Europe Ophthalmic Steroids Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Ophthalmic Steroids Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Ophthalmic Steroids Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Ophthalmic Steroids Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Ophthalmic Steroids Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Alimera Sciences
- 8.1.1 Alimera Sciences Company Information
- 8.1.2 Alimera Sciences Business Overview
- 8.1.3 Alimera Sciences Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Alimera Sciences Ophthalmic Steroids Drug Product Portfolio
- 8.1.5 Alimera Sciences Recent Developments
- 8.2 Allergan
- 8.2.1 Allergan Company Information
- 8.2.2 Allergan Business Overview
- 8.2.3 Allergan Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Allergan Ophthalmic Steroids Drug Product Portfolio
- 8.2.5 Allergan Recent Developments
- 8.3 Bausch and Lomb
- 8.3.1 Bausch and Lomb Company Information
- 8.3.2 Bausch and Lomb Business Overview
- 8.3.3 Bausch and Lomb Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Bausch and Lomb Ophthalmic Steroids Drug Product Portfolio
- 8.3.5 Bausch and Lomb Recent Developments
- 8.4 Genentech
- 8.4.1 Genentech Company Information
- 8.4.2 Genentech Business Overview
- 8.4.3 Genentech Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Genentech Ophthalmic Steroids Drug Product Portfolio
- 8.4.5 Genentech Recent Developments
- 8.5 Novartis AG
- 8.5.1 Novartis AG Company Information
- 8.5.2 Novartis AG Business Overview
- 8.5.3 Novartis AG Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Novartis AG Ophthalmic Steroids Drug Product Portfolio
- 8.5.5 Novartis AG Recent Developments
- 8.6 Regeneron Pharmaceuticals
- 8.6.1 Regeneron Pharmaceuticals Company Information
- 8.6.2 Regeneron Pharmaceuticals Business Overview
- 8.6.3 Regeneron Pharmaceuticals Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Regeneron Pharmaceuticals Ophthalmic Steroids Drug Product Portfolio
- 8.6.5 Regeneron Pharmaceuticals Recent Developments
- 8.7 Valeant Pharmaceuticals International
- 8.7.1 Valeant Pharmaceuticals International Company Information
- 8.7.2 Valeant Pharmaceuticals International Business Overview
- 8.7.3 Valeant Pharmaceuticals International Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Valeant Pharmaceuticals International Ophthalmic Steroids Drug Product Portfolio
- 8.7.5 Valeant Pharmaceuticals International Recent Developments
- 8.8 Bayer AG
- 8.8.1 Bayer AG Company Information
- 8.8.2 Bayer AG Business Overview
- 8.8.3 Bayer AG Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Bayer AG Ophthalmic Steroids Drug Product Portfolio
- 8.8.5 Bayer AG Recent Developments
- 8.9 GlaxoSmithKline
- 8.9.1 GlaxoSmithKline Company Information
- 8.9.2 GlaxoSmithKline Business Overview
- 8.9.3 GlaxoSmithKline Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 GlaxoSmithKline Ophthalmic Steroids Drug Product Portfolio
- 8.9.5 GlaxoSmithKline Recent Developments
- 8.10 Pfizer
- 8.10.1 Pfizer Company Information
- 8.10.2 Pfizer Business Overview
- 8.10.3 Pfizer Ophthalmic Steroids Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Pfizer Ophthalmic Steroids Drug Product Portfolio
- 8.10.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Ophthalmic Steroids Drug Value Chain Analysis
- 9.1.1 Ophthalmic Steroids Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Ophthalmic Steroids Drug Production Mode & Process
- 9.2 Ophthalmic Steroids Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Ophthalmic Steroids Drug Distributors
- 9.2.3 Ophthalmic Steroids Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst